Brien Holden Vision Institute licensed products are protected by intellectual property rights around the world. Our Patent Portfolio In March 2019, BHVI engaged Dr Arthur Back as its head of technology. Working with Dr Arthur Ho, Professor Padmaja Sankaridurg, Hassan Esfandiarijahromi and a team of optometrists and vision scientists, Dr Back has breathed new life into BHVI’s patent portfolio.US Patent 11,061,253 B2 (Ophthalmic lenses for reducing, minimizing, and/or eliminating interference on in-focus images by out-of-focus light) was published in July 2021. The work of Dr Arthur Back and Hassan Esfandiarijahromi, the abstract describes it as:An ophthalmic lens comprising: at least one first optical zone with a first axis, the at least one first optical zone being configured such that, in use with an eye, at least a portion of light passing through the at least one first optical zone is refracted to a first focal point on the first axis; and at least one second optical zone configured such that, in use with the eye, at least a portion of light passing through the at least one second optical zone is refracted to one or more focal points positioned off-axis relative to the first focal point and on at least one focal plane different than a focal plane corresponding to the first focal point; wherein the at least one second optical zone is configured such that the light extending beyond the one or more focal points provides extended depth of focus.It supports a new generation of contact lenses, spectacle lenses and IOLs that may reduce and/or eliminate the effects of optical disorders including myopia and presbyopia.Other applications and PCTs filed during Dr Back’s tenure encompass:Geometrically defined shapes and/or contour optical elements for ophthalmic lenses and methods for creating such geometrically defined shapes and/or contour optical elementsOphthalmic Devices, systems and/or methods for management of ocular conditions and/or reducing night vision disturbancesOphthalmic lenses and methods for correcting, slowing, reducing, and/or controlling the progression of myopia in conjunction with atropine or related compoundsIntraocular Lenses for Reducing Peripheral Pseudophakic DysphotopsiaOphthalmic Devices, systems and/or methods for management of ocular conditions and/or reducing night vision disturbancesOphthalmic Lenses using Binary Amplitude ModulationPharmaceutical Compositions and/or methods for Presbyopia, Mydriasis and/or ocular discomfort managementPharmaceutical Compositions For Controlling And/Or Reducing The Progression Of Myopia Intellectual Property Information BHVI licensed products are protected by intellectual property rights around the world, including but not limited to the below-listed U.S. Patents. The following is provided to satisfy the constructive notice provisions of various jurisdictions, including but not limited to the patent marking provisions of 35 U.S.C. § 287. By specifically listing certain intellectual property rights for certain Brien Holden Vision Institute licensed products below, Brien Holden Vision Institute makes no representation that other relevant intellectual property rights do not exist or may be pending nor that other Brien Holden Vision Institute licensed products not listed here may be protected by one or more intellectual property rights.The Brien Holden Vision Institute licensed products listed below are protected by one or more of the noted intellectual property rights. Licensed Products Last updated 12th December 2019 Intellectual Property Rights U.S. Pat. Nos. 10,203,522; 10,209,535AU Pat. Nos. 2013243247; 2014262297; 2013202694CN Pat. Nos. 201380051988.8; 201320641545.1; 201380027340.7NZ Pat. Nos. 700751FR Pat. Nos. 2989179SG Pat. Nos. 11201406325T; 11201502115RZA Pat. Nos. 2014/07395TW Pat. Nos. I588560; I600418Other patents pending.